Organogenesis Holdings Inc. — Q1 2022 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2022, compared with Q1 2021. Organogenesis develops, manufactures and sells regenerative medicine products in Advanced Wound Care and Surgical & Sports Medicine. It reports as one operating segment.
Key financial results
Amounts in millions of dollars, except percentages and per-share data.
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Net revenue | $98.1 | $102.6 |
| Gross profit / gross margin | $73.0 / 74.4% | $77.1 / 75.1% |
| Operating income / margin | $0.9 / 0.9% | $12.6 / 12.3% |
| Net income | $0.1 | $9.9 |
| Diluted EPS | $0.00 | $0.07 |
| Operating cash flow | $1.4 | $(1.3) |
| Capital expenditures | $6.7 | $5.0 |
| Adjusted EBITDA (non-GAAP) | $5.0 | $16.0 |
Balance sheet and liquidity: At March 31, 2022, cash and cash equivalents were $107.9 million (restricted cash: $0.6 million), working capital was $141.1 million, and current assets were $217.9 million against current liabilities of $76.8 million. Term-loan borrowings were $73.6 million gross ($73.0 million net of discount and issuance costs); no revolving borrowings were outstanding, and $125 million was available under the revolving facility. The company reported compliance with its debt covenants. Management expected available liquidity and cash flows to fund operations, capital spending and debt service for at least 12 months beyond the filing date.
Material changes versus Q1 2021
- Revenue declined 4%, or $4.4 million. Advanced Wound Care revenue was nearly flat at $91.0 million; Surgical & Sports Medicine revenue fell 39% to $7.2 million.
- PuraPly revenue rose to $53.3 million from $41.3 million, attributed to sales-force expansion, more sites of care and adoption of product line extensions.
- Gross profit decreased 5% to $73.0 million, reflecting lower Surgical & Sports Medicine sales and higher manufacturing-related costs.
- SG&A increased 9% to $63.6 million, primarily from additional headcount, travel and marketing. R&D increased 38% to $8.6 million, reflecting staffing, pipeline product costs and clinical studies.
- Operating income fell to $0.9 million and net income to $0.1 million, from $12.6 million and $9.9 million, respectively. Lower interest expense—$0.7 million versus $2.5 million—partly offset the operating decline.
- Operating cash flow improved to $1.4 million from a $1.3 million use, but investing outflows of $6.7 million, mainly capital expenditures, contributed to a $6.0 million decline in cash, cash equivalents and restricted cash during the quarter.
Outlook, risks and unusual items
- Business outlook: The filing gives no specific revenue or earnings guidance. Management expects SG&A and R&D investment to continue as the company expands sales and advances product development. Q1 results are not necessarily indicative of full-year results.
- Product and regulatory exposure: Commercial distribution of ReNu and NuCel ceased after the FDA enforcement grace period ended May 31, 2021. ReNu remains in clinical development; development of NuCel was discontinued. Dermagraft manufacturing was suspended in Q4 2021, and sales were expected to be suspended in Q2 2022 during a planned transition to Massachusetts facilities. Management expects customers may substitute Apligraf, but cautioned that failure to achieve savings or substitution could harm revenue and results.
- Restructuring: A March 2022 plan to restructure Birmingham operations is expected to be completed by year-end and incur approximately $3.0 million of charges, including employee retention and exit costs. Q1 restructuring expense was $0.3 million.
- COVID-19: The company said the pandemic had not materially adversely affected results through Q1 2022, but its future effects remain uncertain.
- Controls: Management concluded internal control over financial reporting was not effective at March 31, 2022 because a previously reported material weakness remained. Deficiencies included formal accounting and IT controls, review procedures and segregation of duties; management cited turnover as a contributing factor. Remediation plans include a new ERP system, additional training, outside testing support and continued monitoring.
- Other items: The CPN acquisition earnout liability remained at zero following a reassessment of the product portfolio outlook. In April 2022, the company released $1.436 million of deferred acquisition consideration through $0.739 million in cash and 203,485 shares. The company reported no material legal proceedings; it accrued $0.15 million for certain pending lawsuits and assessed ordinary-course claims as not expected to have a material effect.
- Debt and market risks: The term loan has variable interest rates, financial covenants and a maturity date of August 2026. Substantially all company assets, including intellectual property, secure the credit agreement. Management said a 10% immediate interest-rate change would not materially affect results or financial position.
Investor verification priorities
- Confirm whether Advanced Wound Care growth, particularly PuraPly, can offset the continued Surgical & Sports Medicine decline and Dermagraft interruption.
- Track gross margin, manufacturing costs, SG&A and R&D spending against revenue growth and profitability.
- Review cash conversion and capital expenditure needs, alongside term-loan amortization, variable-rate exposure and covenant compliance.
- Monitor the Dermagraft manufacturing transition, expected cost savings, customer substitution to Apligraf, and ReNu’s clinical and regulatory progress.
- Verify remediation and sustained operating effectiveness of financial-reporting controls, including the planned ERP implementation.